Spiegl-Kreinecker et al. further reported sensitivity of TERT promotor mutated meningiomas to the E-twenty-six (ETS) transcription factor inhibitor YK-4–279, indicating TERT promotor mutations also as a potential predictive marker for targeted therapies [31]. The gene discussed is TERT; the disease is meningioma.